Gilead
Research
Research
Our growing pipeline includes novel investigational medications for the potential treatment of HIV, hepatitis B and C, respiratory and cardiopulmonary diseases.

Recent News

Visit Gilead’s newsroom for access to our most recent news.

At Gilead, we are dedicated to advancing the care of patients suffering from life-threatening diseases worldwide. Our research and development programs currently focus on small molecule therapeutics for the potential treatment of HIV, hepatitis B and C and cardiovascular diseases. The company also has an active research program in inhaled therapeutics for the treatment of cystic fibrosis-related lung infections. Click here, to learn more about our ongoing research programs.

Tenofovir disoproxil fumarate
Potential indication: Hepatitis B
Awaiting FDA Action
Aztreonam Lysine for inhalation
Potential indication: Cystic Fibrosis
Awaiting FDA Action
Darusentan
Potential indication: Resistant Hypertension
Phase III
Elvitegravir (GS 9137)
Potential indication: HIV/AIDS
Phase II
GS 9450 (LB84451; caspase inhibitor)
Potential indication: Hepatitis C/Fibrosis
Phase II
GS 9131 (nucleotide prodrug)
Potential indication: HIV/AIDS
Phase I
GS 9190 (polymerase inhibitor)
Potential indication: Hepatitis C
Phase I
GS 9191 (nucleotide prodrug)
Potential indication: HPV
Phase I
GS 9310/11 (inhaled fosfomycin/tobramycin)
Potential indication: Bronchiectasis/Cystic Fibrosis
Phase I
GS 9219 (nucleotide prodrug)
Potential indication: Hematologic Cancers
Phase I
Small Molecule Therapeutics
Potential indication: Viral Infections
Preclinical
Small Molecule Therapeutics
Potential indication: Cardiovascular
Preclinical
Inhaled Therapeutics
Potential indication: Respiratory Infections
Preclinical